Actively Recruiting
Psoriatic Immune Response to Tildrakizumab Treatment in Moderate to Severe Psoriasis
Led by University of California, San Francisco · Updated on 2026-06-04
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
S
Sun Pharmaceutical Industries Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to study how the immune cells in the skin and blood of people with moderate to severe psoriasis respond to treatment with the IL-23 blocker tildrakizumab. The study is open-label and will include 10 participants to better understand changes in immune function related to psoriasis during treatment. Participants will receive tildrakizumab, an IL-23 inhibitor, as the experimental treatment. Before and during treatment, skin biopsies and blood samples will be collected for detailed molecular analysis to identify changes in immune cell activity. This study focuses on identifying immune signatures corrected by tildrakizumab. During the study, researchers will assess changes in psoriasis severity using the Psoriasis Area and Severity Index (PASI) score at the start and after 3 months of treatment. Participants will undergo biopsy and blood collection at specified time points for immune profiling. The total study duration covers at least 3 months of treatment with ongoing monitoring of immune function.
CONDITIONS
Brief Title
Psoriatic Immune Response to Tildrakizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Moderate to severe psoriasis affecting more than 5% of body surface area
You will not qualify if you...
- Taking systemic immunosuppressive medications within the last 4 weeks
- Pregnancy
- Severe immunodeficiency from genetic or infectious causes
- Tuberculosis or other active serious infections
- Active systemic malignancy
- Breastfeeding
- Any other condition or abnormality that may compromise patient safety or data quality as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants receive tildrakizumab and undergo biopsy and blood sample collections before and during treatment to assess immune response.
Visits at baseline and at 3 months for assessments and sample collections
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
R
Raymond Cho, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here